Every stroke begins with a sudden interruption of blood flow in the brain. But what happens afterward—why neurons continue to lose function and die over the following days—has remained one of the most ...
Further results from the OCEANIC-STROKE trial have shown that the investigational Factor XIa inhibitor, asundexian (Bayer), not only reduces the risk of recurrent ischemic stroke but also lessens the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results